Explore more publications!

Health Wire East Timor: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire East Timor.

Press releases published on January 13, 2026

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Kaneka Medical America LLC Announces U.S. Launch of WaveSelect 1014 Guidewire
Southern Pain and Spine Specialists Announces Dr. Ammar Alamarie, MD Named Castle Connolly Top Doctor for Pain Management in 2025 for Second Consecutive Year
OC WASTE & RECYCLING PARTNERS WITH AGROMIN TO EXPAND  COMPOST AND MULCH PROGRAM
The Ebony Canal Scores NAACP Image Award Nomination for Outstanding Short Form Documentary
Metabo Drops Examined: Is It Legit for Weight Loss? Safety Checks and Consumer Analysis 2026
La FDA américaine accorde la désignation  « Breakthrough Therapy » à l’IPN60340 (ICT01) d’Ipsen dans la leucémie myéloïde aiguë de première ligne chez les patients inéligibles à une chimiothérapie intensive
U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia
Blue Cross and Blue Shield of Minnesota Adds Virtual Primary Care from Doctor On Demand to Provider Network
Allsup Veterans Appeals Urges Veterans to Take Action on Denied and Underrated VA Claims Before Appeal Deadline Closes
Synfini Assessed ‘Awardable’ for DARPA ERIS Marketplace
Evaluation Finds Significant Quality Improvements in Independent Practices Across Los Angeles
American Case Management Association Opens Registration for the 2026 National Conference
NASM Data Reveals the End of the "Before & After" Photo: Longevity Overtakes Aesthetics as Top Fitness Goal
WOWorks Defines Better-for-You Dining in 2026 with Protein-Rich, Customizable Menus
Minovia Therapeutics Announces Two New U.S. Patents Granted, Strengthening Its Mitochondrial Augmentation Therapy Platform
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions